Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

Abstract Background Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with...

Full description

Bibliographic Details
Main Authors: Chia-Yu Chang, Yung-Hsin Yeh, Yi-Hsin Chan, Jia-Rou Liu, Shang-Hung Chang, Hsin-Fu Lee, Lung-Sheng Wu, Kun-Chi Yen, Chi-Tai Kuo, Lai-Chu See
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Cardiovascular Diabetology
Subjects:
Dipeptidyl peptidase-4 inhibitor
Type 2 diabetes mellitus
Atrial fibrillation
Online Access:http://link.springer.com/article/10.1186/s12933-017-0640-5

Internet

http://link.springer.com/article/10.1186/s12933-017-0640-5

Similar Items